MX2022012278A - Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes. - Google Patents

Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.

Info

Publication number
MX2022012278A
MX2022012278A MX2022012278A MX2022012278A MX2022012278A MX 2022012278 A MX2022012278 A MX 2022012278A MX 2022012278 A MX2022012278 A MX 2022012278A MX 2022012278 A MX2022012278 A MX 2022012278A MX 2022012278 A MX2022012278 A MX 2022012278A
Authority
MX
Mexico
Prior art keywords
variable domains
single variable
immunoglobulin single
purification
production
Prior art date
Application number
MX2022012278A
Other languages
English (en)
Inventor
Ann Brigé
Florian Madura
Sonia Letestu
Tom Merchiers
Horen Ellen Van
Chakib Borsali
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2022012278A publication Critical patent/MX2022012278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8624—Detection of slopes or peaks; baseline correction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a un método mejorado para la fabricación de polipéptidos que comprenden al menos tres o al menos cuatro dominios variables individuales de inmunoglobulina (ISVD). Más específicamente, se proporciona un método mejorado para producir polipéptidos purificados y aislados que comprenden al menos tres o al menos cuatro ISVDs en los que una variante conformacional no deseada relacionada con el producto está reducida o ausente.
MX2022012278A 2020-03-30 2021-03-30 Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes. MX2022012278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20166803 2020-03-30
PCT/EP2021/058302 WO2021198260A1 (en) 2020-03-30 2021-03-30 Method for the production and purification of multivalent immunoglobulin single variable domains

Publications (1)

Publication Number Publication Date
MX2022012278A true MX2022012278A (es) 2022-10-27

Family

ID=70058271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012278A MX2022012278A (es) 2020-03-30 2021-03-30 Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.

Country Status (12)

Country Link
US (1) US20230136595A1 (es)
EP (1) EP4126971A1 (es)
JP (2) JP2023519967A (es)
KR (1) KR20230005847A (es)
CN (1) CN115397868A (es)
AU (1) AU2021246890A1 (es)
BR (1) BR112022018364A2 (es)
CA (1) CA3175873A1 (es)
IL (1) IL296767A (es)
MX (1) MX2022012278A (es)
TW (1) TW202204423A (es)
WO (1) WO2021198260A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020397210A1 (en) * 2019-12-06 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting TNFa and OX40L
KR20260068087A (ko) 2023-09-04 2026-05-13 사노피 글리피칸-3-발현 종양의 치료에 사용하기 위한 폴리펩티드

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
CN1830999A (zh) * 2000-11-27 2006-09-13 Rmf迪克塔吉恩有限公司 对化学合成多肽进行折叠的方法
BRPI0415887B1 (pt) 2003-10-27 2021-01-26 Wyeth métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CN105646643A (zh) 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
CA2759370C (en) 2009-04-30 2020-02-11 Peter Schotte Method for the production of domain antibodies
US20110262348A1 (en) * 2010-03-29 2011-10-27 Vrije Universiteit Brussel Selective targeting of intratumoral cells
NZ587521A (en) 2010-06-02 2010-10-29 Aquadria Kite Design Ltd An inflatable wing with inflatable leading edge spar and rib(s) from spar to trailing edge in form of inflatable truss(es)
US8895707B2 (en) 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
EP2632946B1 (en) 2010-10-29 2017-12-06 Ablynx N.V. Method for the production of immunoglobulin single variable domains
US20120225072A1 (en) * 2011-03-02 2012-09-06 Ablynx N.V. Stable formulations of immunoglobulin single variable domains and uses thereof
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
KR101602870B1 (ko) * 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
HK1249528A1 (zh) * 2015-02-05 2018-11-02 Ablynx N.V. 通过c-末端合成半胱氨酸连接的纳米抗体二聚体
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
EP3414268A1 (en) * 2016-02-12 2018-12-19 Ablynx NV Method for the production of immunoglobulin single variable domains
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
WO2018183972A2 (en) * 2017-04-01 2018-10-04 Massachusetts Institute Of Technology Systems and methods for using behavior data of impurities and target proteins to design downstream processes
IL270951B2 (en) * 2017-06-02 2025-05-01 Merck Patent Gmbh ADAMTS5, MMP13 and aggrecan-binding polypeptides
HUP2100233A1 (hu) * 2021-06-16 2023-10-28 Pannon Egyetem Integrált módszer a vizelet prosztata-specifikus antigén N-glikozilációs profiljának kapilláris elektroforézissel történõ meghatározására

Also Published As

Publication number Publication date
WO2021198260A1 (en) 2021-10-07
JP2023519967A (ja) 2023-05-15
JP2026016482A (ja) 2026-02-03
CN115397868A (zh) 2022-11-25
BR112022018364A2 (pt) 2022-11-08
EP4126971A1 (en) 2023-02-08
TW202204423A (zh) 2022-02-01
US20230136595A1 (en) 2023-05-04
AU2021246890A1 (en) 2022-12-01
IL296767A (en) 2022-11-01
KR20230005847A (ko) 2023-01-10
CA3175873A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
MX2022001960A (es) Metodos para producir celulas progenitoras hemogenicas a partir de celulas madre pluripotenciales.
ZA200707234B (en) Screening method,process for purifying of non-diffusible a-beta oligomers,selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
MX2009007515A (es) Produccion de biocombustible y proteina a partir de una materia prima.
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
WO2002099067A3 (en) Gene expression and production of tgf-b proteins including bioactive mullerian inhibiting substance from plants
BR112022023697A2 (pt) Métodos e meios para a produção de moléculas semelhantes a ig
EA201890004A1 (ru) Способ производства высокореактивного цемента
MX2025005627A (es) Anticuerpos que se unen al componente de complemento 1s (c1s) y usos de estos
MX2023002960A (es) Tecnologia de proceso para fabricacion de productos biologicos y purificacion aguas abajo.
PH12021553116A1 (en) Process for the purification of lacto-n-neotetraose
EP4621061A4 (en) PROCESS FOR THE PRODUCTION OF PSICOSE BY FERMENTATION AND ISOMERIZATION OF BACILLUS SUBTILIS
AU5744501A (en) Novel immunoadhesin for the prevention of rhinovirus infection
MX393907B (es) Modificacion cristalina metaestable y metodo para llevarla a cabo (i)
WO2011090720A3 (en) Purification of proteins
GB202219638D0 (en) Protein expression system, method of producing proteins, proteins produced thereby, and use thereof
WO2004024098A3 (en) Method for the treatment of nephritis using anti-pdgf-dd antibodies
MX2022002558A (es) Ingrediente modificador del sabor derivado de la proteina de arroz.
BR112022018364A2 (pt) Método para produção e purificação de domínios variáveis únicos de imunoglobulina multivalente
DE60314132D1 (de) Methode zur produktion monoklonaler antikörper
WO2006091731A3 (en) Processes for the preparation of linezolid intermediate
MX2024015744A (es) Proteina de exportacion de l-histidina y metodo de produccion de l-histidina utilizando la misma
EP4118093A4 (en) METHOD FOR PURIFYING A FC FUSION PROTEIN
ATE468349T1 (de) GROßTECHNISCHES VERFAHREN ZUR HERSTELLUNG VON 17- HYDROXY-6BETA, 7BETA, 15BETA,16BETA-BISMETHYLEN-3-OXO-17ALPHA-PREGN-4 EN-21-CARBONSÄURE-GAMMA- LACTON UND SCHLÜSSELZWISCHENPRODUKTE FÜR DIESES VERFAHREN
ATE459614T1 (de) Herstellungsverfahren für pyrazolhaltige verbindungen
HUP0400166A1 (hu) Eljárás keményítő vagy keményítőt tartalmazó termékek előállítására növényi nyersanyagokból